ALDH1A3 and neoplasm: In addition, we performed tumor immune dysfunction and exclusion (TIDE) prediction, which showed that the TIDE score was higher in the group with low expression of ALDH1A3, suggesting that these patients responded less well to immunotherapy (Figure 4G).